“3 doses offer reasonable protection” “The new version of Shot which will cover Omicron will be ready in March”
Pfizer CEO Albert Bourla said on Monday that two doses of the company’s vaccine may not offer strong protection against infection with the omicron Covid variant, and that the original injections have also lost some of their effectiveness for prevent hospitalization.
Bourla, in an interview with the JP Morgan Healthcare Conference, stressed the importance of a third blow to strengthen people’s protection against omicron.
“The two doses, they are not enough for omicron,” Bourla said. “The third dose of the current vaccine offers fairly good protection against death and decent protection against hospitalizations. “
Bourla said the omicron is a more difficult target than previous variants. Omicron, which has dozens of mutations, may escape some of the protection offered by Pfizer’s original two injections.
Bourla told CNBC earlier Monday that Pfizer would have a vaccine that specifically targets omicron ready in March, although he said it was not clear whether or not it would be needed.
Bourla also told CNBC that more testing needed to be done to determine whether or not a fourth dose was needed.